These results indicate that the novel NRAS A11V variant, but not the KRAS G12S, A59T, and Y137C mutants, inhibits caspase 3/7 activation and promotes resistance to apoptosis in a colorectal cancer cell background. This evidence concerns the gene NRAS and colorectal cancer.